| Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor A Mazumdar, RA Wang, SK Mishra, L Adam, R Bagheri-Yarmand, ... Nature cell biology 3 (1), 30-37, 2001 | 470 | 2001 |
| Antiproliferative effects of honey and of its polyphenols: a review SK Jaganathan, M Mandal BioMed Research International 2009 (1), 830616, 2009 | 458 | 2009 |
| Cell cycle-dependent modulation of telomerase activity in tumor cells. X Zhu, R Kumar, M Mandal, N Sharma, HW Sharma, U Dhingra, ... Proceedings of the National Academy of Sciences 93 (12), 6091-6095, 1996 | 420 | 1996 |
| Regulatable expression of p21-activated kinase-1 promotes anchorage-independent growth and abnormal organization of mitotic spindles in human epithelial breast cancer cells RK Vadlamudi, L Adam, RA Wang, M Mandal, D Nguyen, A Sahin, ... Journal of Biological Chemistry 275 (46), 36238-36244, 2000 | 317 | 2000 |
| Regulation of cyclooxygenase-2 pathway by HER2 receptor R Vadlamudi, M Mandal, L Adam, G Steinbach, J Mendelsohn, R Kumar Oncogene 18 (2), 305-314, 1999 | 308 | 1999 |
| A naturally occurring MTA1 variant sequesters oestrogen receptor-α in the cytoplasm R Kumar, RA Wang, A Mazumdar, AH Talukder, M Mandal, Z Yang, ... Nature 418 (6898), 654-657, 2002 | 291 | 2002 |
| Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells D Bandyopadhyay, M Mandal, L Adam, J Mendelsohn, R Kumar Journal of Biological Chemistry 273 (3), 1568-1573, 1998 | 286 | 1998 |
| Bcl-2 modulates telomerase activity M Mandal, R Kumar Journal of Biological Chemistry 272 (22), 14183-14187, 1997 | 283 | 1997 |
| The potential of celecoxib-loaded hydroxyapatite-chitosan nanocomposite for the treatment of colon cancer P Venkatesan, N Puvvada, R Dash, BNP Kumar, D Sarkar, B Azab, ... Biomaterials 32 (15), 3794-3806, 2011 | 280 | 2011 |
| Epithelial to mesenchymal transition in head and neck squamous carcinoma: association of Src activation with E‐cadherin down‐regulation, vimentin expression, and aggressive … M Mandal, JN Myers, SM Lippman, FM Johnson, MD Williams, S Rayala, ... Cancer 112 (9), 2088-2100, 2008 | 249 | 2008 |
| Autophagy: cancer’s friend or foe? SK Bhutia, S Mukhopadhyay, N Sinha, DN Das, PK Panda, SK Patra, ... Advances in cancer research 118, 61-95, 2013 | 232 | 2013 |
| Cancer development, chemoresistance, epithelial to mesenchymal transition and stem cells: A snapshot of IL-6 mediated involvement R Bharti, G Dey, M Mandal Cancer letters 375 (1), 51-61, 2016 | 230 | 2016 |
| Apoptotic effect of eugenol in human colon cancer cell lines SK Jaganathan, A Mazumdar, D Mondhe, M Mandal Cell biology international 35 (6), 607-615, 2011 | 223 | 2011 |
| Regulation of microfilament reorganization and invasiveness of breast cancer cells by kinase dead p21-activated kinase-1 L Adam, R Vadlamudi, M Mandal, J Chernoff, R Kumar Journal of Biological Chemistry 275 (16), 12041-12050, 2000 | 218 | 2000 |
| Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer BA Schiff, AB McMurphy, SA Jasser, MN Younes, D Doan, OG Yigitbasi, ... Clinical cancer research 10 (24), 8594-8602, 2004 | 206 | 2004 |
| Exosome as a novel shuttle for delivery of therapeutics across biological barriers CK Das, BC Jena, I Banerjee, S Das, A Parekh, SK Bhutia, M Mandal Molecular pharmaceutics 16 (1), 24-40, 2018 | 198 | 2018 |
| An ethnobotanical study of traditional anti-inflammatory plants used by the Lohit community of Arunachal Pradesh, India ND Namsa, H Tag, M Mandal, P Kalita, AK Das Journal of ethnopharmacology 125 (2), 234-245, 2009 | 198 | 2009 |
| Overexpression of HER2 modulates bcl-2, bcl-XL, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells. R Kumar, M Mandal, A Lipton, H Harvey, CB Thompson Clinical cancer research: an official journal of the American Association …, 1996 | 197 | 1996 |
| Improvement of cellular uptake, in vitro antitumor activity and sustained release profile with increased bioavailability from a nanoemulsion platform H Choudhury, B Gorain, S Karmakar, E Biswas, G Dey, R Barik, M Mandal, ... International Journal of Pharmaceutics 460 (1-2), 131-143, 2014 | 194 | 2014 |
| PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes I Pal, M Mandal Acta Pharmacologica Sinica 33 (12), 1441-1458, 2012 | 191 | 2012 |
Goutam DeyPost Doctoral Fellow, Cleveland Clinic, Lerner Research Institute, Cleveland, Ohio, USA在 ccf.org 的电子邮件经过验证
